Aristolochic acid and the etiology of endemic (Balkan) nephropathy AP Grollman, S Shibutani, M Moriya, F Miller, L Wu, U Moll, N Suzuki, ... Proceedings of the National Academy of Sciences 104 (29), 12129-12134, 2007 | 689 | 2007 |
p63 and p73: roles in development and tumor formation UM Moll, N Slade Molecular cancer research 2 (7), 371-386, 2004 | 632 | 2004 |
ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors AI Zaika, N Slade, SH Erster, C Sansome, TW Joseph, M Pearl, E Chalas, ... The Journal of experimental medicine 196 (6), 765-780, 2002 | 451 | 2002 |
Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid B Jelaković, S Karanović, I Vuković-Lela, F Miller, KL Edwards, J Nikolić, ... Kidney international 81 (6), 559-567, 2012 | 250 | 2012 |
Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo N Concin, K Becker, N Slade, S Erster, E Mueller-Holzner, H Ulmer, ... Cancer research 64 (7), 2449-2460, 2004 | 206 | 2004 |
TP53 Mutational signature for aristolochic acid: an environmental carcinogen M Moriya, N Slade, B Brdar, Z Medverec, K Tomic, B Jelaković, L Wu, ... International journal of cancer 129 (6), 1532-1536, 2011 | 127 | 2011 |
Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer G Hofstetter, A Berger, H Fiegl, N Slade, A Zorić, B Holzer, E Schuster, ... Oncogene 29 (13), 1997-2004, 2010 | 100 | 2010 |
The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease MJ Jembrek, N Slade, PR Hof, G Šimić Progress in neurobiology 168, 104-127, 2018 | 89 | 2018 |
p53 mutations as fingerprints for aristolochic acid–an environmental carcinogen in endemic (Balkan) nephropathy N Slade, UM Moll, B Brdar, A Zorić, B Jelaković Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 663 (1 …, 2009 | 72 | 2009 |
Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival S Kapitanović, S Radošević, N Slade, M Kapitanović, Š Anđelinović, ... Journal of cancer research and clinical oncology 126, 205-211, 2000 | 68 | 2000 |
Novel Derivatives of Benzo[b]thieno[2,3-c]quinolones: Synthesis, Photochemical Synthesis, and Antitumor Evaluation J Dogan Koružnjak, M Grdiša, N Slade, B Zamola, K Pavelić, ... Journal of medicinal chemistry 46 (21), 4516-4524, 2003 | 51 | 2003 |
ΔNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation N Slade, AI Zaika, S Erster, UM Moll Cell Death & Differentiation 11 (3), 357-360, 2004 | 50 | 2004 |
Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers K Becker, P Pancoska, N Concin, K Vanden Heuvel, N Slade, M Fischer, ... International journal of oncology 29 (4), 889-902, 2006 | 45 | 2006 |
Synthesis, photochemical synthesis and antitumor evaluation of novel derivatives of thieno [3′, 2′: 4, 5] thieno [2, 3-c] quinolones J DoganKoruznjak, N Slade, B Zamola, K Pavelic, G Karminski-Zamola Chemical and pharmaceutical bulletin 50 (5), 656-660, 2002 | 44 | 2002 |
Mutational processes in hepatocellular carcinoma: the story of aristolochic acid JC Nault, E Letouzé Seminars in liver disease 39 (03), 334-340, 2019 | 30 | 2019 |
The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis MK Florijan, P Ozretić, M Bujak, L Pezzè, Y Ciribilli, Ž Kaštelan, N Slade, ... Urologic Oncology: Seminars and Original Investigations 37 (9), 578. e1-578. e10, 2019 | 22 | 2019 |
Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines P Ozretić, N Hanžić, B Proust, M Sabol, D Trnski, M Radić, V Musani, ... Scientific reports 9 (1), 12470, 2019 | 22 | 2019 |
Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis A Zorić, A Horvat, N Slade Carcinogenesis 34 (3), 522-529, 2013 | 22 | 2013 |
Mutational analysis of p53 in human tumors: immunocytochemistry N Slade, UM Moll p53 Protocols, 231-243, 2003 | 22 | 2003 |
Altered expression of shorter p53 family isoforms can impact melanoma aggressiveness A Tadijan, F Precazzini, N Hanžić, M Radić, N Gavioli, I Vlašić, P Ozretić, ... Cancers 13 (20), 5231, 2021 | 19 | 2021 |